

CURRICULUM VITAE

EUROPEAN FORMAT FOR CURRICULUM VITAE



PERSONAL INFORMATION

Name and Surname

Date of birth

Telephone

E-mail

Current Position

Giuseppe Procopio

SSD Genitourinary Oncology Chief at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan

EDUCATION AND QUALIFICATION

- Date
- Name of Institution
- Qualification

2023
National Scientific Qualification - Ministry of University and Research (MIUR)
Qualification as Full Professor – Area 6/D3 blood, oncology e rheumatology diseases

- Date
- Name of Institution
- Qualification

1997
University of Messina (UniME)
Specialty in Medical Oncology

- Date
- Name of Institution
- Qualification

1992
University of Messina (UniME)
Degree in Medicine and Surgery

PROFESSIONAL EXPERIENCES

- Date (from – to)
- Employer name and address
- Type of company or department
- Position
- Date (from – to)
- Employer name and address

APRIL 2022 – ONGOING
Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milan
Medical Oncology
SSD Genitourinary Oncology Chief
NOVEMBER 2022 – MARCH 2023
Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milan

- Type of company or department
 - Position
 - Date (from – to)
 - Employer name and address
- Medical Oncology
- SS Genitourinary Oncology Chief
- NOVEMBER 2022 – ONGOING
- Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
-
- Type of company or department
 - Position
 - Date (from – to)
 - Employer name and address
- Prostate Program – Scientific Direction Special Project
- Director
- MAY - OCTOBER 2022
- Cremon Hospital, ASST Cremona, Viale Concordia 1, Cremona
-
- Type of company or department
 - Position
 - Date (from – to)
 - Employer name and address
- Medical Oncology
- SC Medical Oncology Director
- 2013 – 2022
- Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
-
- Type of company or department
 - Position
 - Date (from – to)
 - Employer name and address
- Medical Oncology
- SS Genitourinary Oncology
- 2000 – 2013
- Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
-
- Type of company or department
 - Tipo di impiego
 - Date (from – to)
 - Employer name and address
- Medical Oncology
- Staff Physician
- 1998-1999
- Fondazione IRCCS Istituto Nazionale dei Tumori – Via G. Venezian 1, Milano
-
- Type of company or department
 - Position
- Medical Oncology
- Associate Researcher

OTHER

SCIENTIFIC ACTIVITY:

The scientific activity is focused on Genitourinary neoplasms.

He is author/coauthor of **more than 290 scientific publications, more than 150 on renal carcinoma** and more than 130 just in the last 5 years.

His **H index is 40**, with **10.814 citations**. (Last Update on 15th of June 2023)

He is Principal Investigator (until 30th of April 2022) of **several clinical studies**, activated since 2014 and **including several multicentric studies on renal carcinoma**.

GRANTS:

He is Principal Investigator/Co-Investigator of **6 No Profit research projects**, managing economic resources amounting to 2.958.000 euro:

- Participant and **Coordinator of Objective 6 "Innovative immunotherapies for renal cell carcinoma"** in the **ImmunoHUB project**, funded by the **Ministry of Health** under the "Trajectory 4 "Biotechnology, Bioinformatics and Pharmaceutical Development - Line of action 4.1 Creation of the Science Hub Life", coordinated by University of Pavia. Agreement T4-CN-02.
- Participant, **Principal Investigator and Coordinator for Italy** in the Horizon Europe research project entitled **"First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma - CARE 1"**, coordinated by Gustave Roussy Institute (France). Proposal number: 101104801, **HORIZON-MISS-2022-CANCER-01** Research and Innovation actions supporting the implementation of the Mission on Cancer, Topic: HORIZON-MISS-2022-CANCER-01-03, Type of Action: HORIZON-RIA. Grant Agreement (GA) N. 101104801.
- **Principal Investigator of the multicenter research project entitled "Multiomics approach for patients stratification and novel target identification in metastatic clear cell renal carcinoma"**, funded by the Italian Association for Cancer Research (**AIRC**) - **Project IG 2021** ID 26108.
- Participant of the **Horizon 2020** research project entitled "Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity - KATY" (<https://katy-project.eu/>), coordinated by Tor Vergata University, funded by the European Commission, Grant Agreement (GA) No: 101017453, Call/Topic: AI for Genomics and Personalized Medicine - Type of action: Research and Innovation action.
- **Principal Investigator** of the research project entitled **"Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)"**, funded by the **Ministry of Health under the Finalized Research 2016 Call** (concluded).
- **Principal Investigator** of the research project entitled **"Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery"** funded by the Italian Association for Cancer Research (**AIRC**) - **Project IG 2014** Id.15792 (concluded).
- Coordinator of SATURNO project "Study: multicenter, prospective, non-interventional Italian registry of Advanced/metastatic Urothelial carcinoma" - Registry of advanced urothelial tumors, promoted by the **Federation of Italian Cooperative Oncology Groups (FICOG)**.

PARTECIPAZIONE A SOCIETÀ SCIENTIFICHE

Positions in important national and international scientific societies:

- Member of the Board of Directors of the Italian Association of Medical Oncology (AIOM) with consecutive mandate from 2015 to 2019
- **Treasurer of the Board of Directors of the Federation of Italian Cooperative Oncology Groups (FICOG)**, a company founded in 2015 which brings together numerous Italian cooperative oncology groups in order to develop and implement clinical research in Italy and internationally.
- **Scientific Secretary, Member of the Board of Directors and outgoing President of MEET-URO: Italian Network for Research in Urologic-Oncology**, an association whose purpose is to bring together experts of Urological Medical Oncology in order to promote its progress in the clinical, experimental and social-welfare fields. Another intention of this association is to facilitate relationships between urology oncology specialists, general practitioners and other specialists in order to establish scientific relationships with similar Italian and international associations. The Association also has the aim of promoting

experimental and clinical research, the quality of oncological treatments and interdisciplinarity.

- Member of the IRCCS San Raffaele of Milan Ethics Committee for Care and Research, which includes IRCCS Policlinico in San Donato Milanese, Galeazzi Orthopedic Institute IRCCS in Milan, San Raffaele Turro in Milan and Sant'Ambrogio Clinic in Milan.
- Member of the Board for the design, review and drafting of the diagnostic and therapeutic care pathways (PDTA) for oncological kidney and prostate pathologies of INTMI
- **Member of the European Society of Medical Oncology (ESMO) Working Group** for the Guidelines drafting on the diagnosis and treatment of localized or advanced stage prostate cancer since 2019 and on the **diagnosis and treatment of localized stage kidney cancer or advanced since 2021.**
- **AIOM Guidelines Coordinator on the diagnosis and treatment of renal tumors.**
- Reviewer of AIOM guidelines on the diagnosis and treatment of prostate cancer
- Member of important scientific societies such as ASCO, ESMO, AIOM.

CONGRESSES PARTECIPATION

In the last 5 years (2018 - 2023) he took part in more than 500 national and international Congresses as Chair, Moderator, Discussant, Speaker and Lecturer.

TEACHING POSITIONS

In addition to the role of lecturer at the School of Specialization in Medical Oncology in the University of Milan, he holds the following teaching positions:

- Lecturer for seminar activities on "Future strategies for the treatment of urological tumors" within the School of Specialization in Medical Oncology of the University of Modena and Reggio Emilia (UNIMORE) – 2023
- Lecturer at Humanitas University, Pieve Emanuele (Milan), within the II level Master's Degree in Therapy with Radioligands, academic year 2022/2023, in collaboration with the Catholic University of the Sacred Heart of Rome and the National Cancer Institute of Milan.
- Lecturer at the International School of Medical sciences at the 54 Course: "Evolving knowledge in the management of solid tumors: from molecular characterization to new therapeutic options in adult and elderly people". Lecture entitled "Advanced prostate cancer treatment: state of art", organized by the Ettore Majorana Foundation and Center for scientific culture with the University of Palermo, with the support of MIUR, the Ministry of Health, the NATO Scientific General Assembly Committee, the Sicily Region, the National Interuniversity Consortium for Bio-Oncology (CINBO) and supported by AIOM as well. ERICE-TRAPANI-SICILY.
- Lecturer in the 16th edition of the II Level University Master "Manager of Pharmaceutical Departments" in the University of Camerino, in collaboration with the Italian Society of Hospital Pharmacy, the Italian Society of Pharmacology, the vast area n. 5 of the ASUR Marche Ascoli Piceno - San Benedetto del Tronto and the Territorial Social Health Authority "Papa Giovanni XXIII", Bergamo 2017.

EDITORIAL ACTIVITIES

He is Section Editor for "Tumori Journal" - Genitourinary section (IF 2,438).

He is Guest Associate Editor for "Frontiers in Oncology" - Section:Genitourinary Oncology (IF 5.738).

He is a member of Editorial Board for "Therapeutic Advances" in Urology (IF 3.130).

He was Associate Editor for "Cancer Breaking News".

He is a Reviewer of scientific journals such as Lancet Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer, Clinical Cancer Research, Cancer Treatment Review, Cancer Medicine and Critical Review Oncology Hematology.

EVALUATIONS OF FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI TECHNICAL BOARD
(Quinquennium)


DATE OF TECHNICAL BOARD: 24TH OF SEPTEMBER 2019

EVALUATION RESULT: EXCELLENT

REFERRED TO: SSD GENITOURINARY ONCOLOGY POSITION



SI



Attachment

Scientific Publications

1. Vignani F, Tambaro R, De Giorgi U, et al. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. *European Urology* 2023;83(1):82–9.
2. Buti S, Basso U, Giannarelli D, et al. Concomitant Drugs Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. *Journal of Immunotherapy* 2023;46(1):22–6.
3. Brunelli M, Tafuri A, Cima L, et al. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *Journal of Clinical Pathology* 2022;75(1):39–44.
4. Mennitto A, Zattarin E, Di Maio M, et al. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). *Expert Review of Anticancer Therapy* 2022;22(1):115–21.
5. Franza A, Claps M, Procopio G. PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls. *Translational Oncology* [Internet] 2022;15(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118832783&doi=10.1016%2fj.tranon.2021.101263&partnerID=40&md5=a2cebd0db3fb3c4c2027db0b6af356b2>
6. Ottini A, Sepe P, Beninato T, et al. Biomarker-driven immunotherapy for precision medicine in prostate cancer. *Personalized Medicine* 2022;19(1):51–66.
7. Caminiti C, Bryce J, Riva S, et al. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). *Tumori* [Internet] 2022; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131596348&doi=10.1177%2f03008916221099558&partnerID=40&md5=714dd8c9e44b50eb33d251b9ef046c76>
8. Nicolai N, Nazzani S, Tesone A, et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: evaluation of safety and efficacy. *Tumori* [Internet]

2022; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135243761&doi=10.1177%2f03008916221112697&partnerID=40&md5=91ee0a002df72df5222274e65258315e>

9. Bottiglieri A, Sepe P, Stellato M, et al. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. *Cancer Management and Research* 2022;14:3071–81.
10. Procopio G, Claps M, Pircher C, et al. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). *Tumori* [Internet] 2022; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143614330&doi=10.1177%2f03008916221138881&partnerID=40&md5=12f64c5782cb6533d5f40050d3683b67>
11. Buti S, Trentini F, Sepe P, et al. BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. *Tumori* [Internet] 2022; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144217676&doi=10.1177%2f03008916221141483&partnerID=40&md5=707ecd26fcf4e2fd2d13b3d1746e5cfc>
12. Rebuzzi SE, Cerbone L, Signori A, et al. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. *Therapeutic Advances in Medical Oncology* [Internet] 2022;14. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125878122&doi=10.1177%2f17588359221079580&partnerID=40&md5=924992bcf6d954fdc5b37ec07770bb89>
13. Masini C, Iotti C, De Giorgi U, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. *European Urology* 2022;81(3):274–82.
14. Thierry-Vuillemin A, de Bono J, Hussain M, et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. *The Lancet Oncology* 2022;23(3):393–405.
15. Iacovelli R, Ciccarese C, Procopio G, et al. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. *Cancer Treatment Reviews* [Internet] 2022;105. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126620741&doi=10.1016%2fj.ctrv.2022.102379&partnerID=40&md5=4f5a2825b8c0ea92d4880c7fc32e2fee>
16. Procopio G, Chiuri VE, Giordano M, et al. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. *ESMO Open* [Internet] 2022;7(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127748445&doi=10.1016%2fj.esmoop.2022.100431&partnerID=40&md5=218ee8f66d9ff120fb46d7063c1d0c8a>
17. Orlacchio A, Guastoni C, Beretta GD, et al. SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). *Radiologia Medica* 2022;127(5):534–42.
18. Basso U, Paolieri F, Rizzo M, et al. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. *Cancers* [Internet] 2022;14(9). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129435973&doi=10.3390%2fcancers14092293&partnerID=40&md5=f93c9a80e838de7415700a083df4f7da>
19. Procopio G, Sepe P, Claps M, et al. Cabozantinib as First-line Treatment in Patients With Metastatic

Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). JAMA Oncology 2022;8(6):910–3.

20. Brunelli M, Martignoni G, Malpeli G, et al. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine [Internet] 2022;12(5). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129938293&doi=10.3390%2fjpm12050727&partnerID=40&md5=1fbb5b6d2b5e85db14aedfc461df2fb6>
21. Russo A, Incorvaia L, Capoluongo E, et al. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open [Internet] 2022;7(3). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130700050&doi=10.1016%2fj.esmoop.2022.100459&partnerID=40&md5=45c7ab78b599651dd88f8e88994a0ec0>
22. Roubaud G, Özgüroğlu M, Penel N, et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. European Journal of Cancer 2022;170:73–84.
23. Roviello G, Gambale E, Giorgione R, et al. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Medicine 2022;11(16):3084–92.
24. Fuoco V, Argiroffi G, Mazzaglia S, et al. Update on radioligand therapy with ¹⁷⁷Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori 2022;108(4):315–25.
25. Roviello G, Catalano M, De Giorgi U, et al. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Frontiers in Oncology [Internet] 2022;12. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137028106&doi=10.3389%2ffonc.2022.918413&partnerID=40&md5=11f552c54bf6cd48d3d3e32f806edd76>
26. Rebuzzi SE, Signori A, Stellato M, et al. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. Frontiers in Oncology [Internet] 2022;12. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139664636&doi=10.3389%2ffonc.2022.955501&partnerID=40&md5=7d3246727e2de2e18c7695c5d59dfc6f>
27. Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2022;23(9):1133–44.
28. Iacovelli R, Ciccarese C, Maruzzo M, et al. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Clinical Genitourinary Cancer 2022;20(5):498.e1-498.e9.
29. Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet 2022;400(10358):1103–16.
30. Catalano M, De Giorgi U, Maruzzo M, et al. Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines [Internet] 2022;10(10). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140584693&doi=10.3390%2fbiomedicines10102444&partnerID=40&md5=b5c9f238d8216070437fe39547f53a1b>
31. Sternberg CN, Shin N, Chernyshov K, et al. Case report: Metastatic urothelial cancer with an exceptional

response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. *Frontiers in Oncology* [Internet] 2022;12. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142110426&doi=10.3389%2ffonc.2022.1006017&partnerID=40&md5=c45b3de04ad46a12e9f6977edd36fb62>

32. Choueiri TK, Kluger H, George S, et al. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. *Journal for ImmunoTherapy of Cancer* [Internet] 2022;10(11). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141223697&doi=10.1136%2fjitc-2022-005780&partnerID=40&md5=2dfa8226076e24fc390cf1cb2277a4ab>
33. Del Re M, Crucitta S, Paolieri F, et al. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. *Journal of Translational Medicine* [Internet] 2022;20(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135914350&doi=10.1186%2fs12967-022-03557-7&partnerID=40&md5=c94d469a337706899ba525d03f23b3a5>
34. Rebutuzzi SE, Signori A, Banna GL, et al. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. *Journal of Translational Medicine* [Internet] 2022;20(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139116878&doi=10.1186%2fs12967-022-03601-6&partnerID=40&md5=d4d945db07583bb28ded7f2825893bf7>
35. Rebutuzzi SE, Signori A, Buti S, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. *ESMO Open* [Internet] 2022;7(6). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144008096&doi=10.1016%2fj.esmoop.2022.100634&partnerID=40&md5=3dcd94db470560461b21ba7fc5224cbd>
36. Franchina V, Cagnazzo C, Di Costanzo A, et al. Patient associations and clinical oncology research: how much does a patient's voice really matter? *Expert Review of Pharmacoeconomics and Outcomes Research* 2021;21(3):433–40.
37. Mennitto A, Verzoni E, Cognetti F, et al. Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. *Expert Review of Clinical Pharmacology* 2021;14(2):261–8.
38. Rebutuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). *Therapeutic Advances in Medical Oncology* [Internet] 2021;13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107317392&doi=10.1177%2f17588359211019642&partnerID=40&md5=20ccb545b8cd422bfade4b1378d0b45>
39. Santoni M, Massari F, Bracarda S, et al. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? *Diagnostics* [Internet] 2021;11(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107976588&doi=10.3390%2fdiagnostics11010138&partnerID=40&md5=0efc8be48ca4491cfccc6cf02b4aa200>
40. Guadalupi V, Cartenì G, Iacovelli R, et al. Second-line treatment in renal cell carcinoma: clinical experience and decision making. *Therapeutic Advances in Urology* [Internet] 2021;13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108145194&doi=10.1177%2f17562872211022870&partnerID=40&md5=53f397e45ba21230b7a3857340815a6f>
41. Bersanelli M, Buti S, Cortellini A, et al. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). *Clinical Medicine Insights: Oncology* [Internet] 2021;15. Available from:

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109725629&doi=10.1177%2f11795549211021667&partnerID=40&md5=9a817ca8b53c4bc60502696ea4679fc>

42. Bersanelli M, Buti S, Rizzo M, et al. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. *Therapeutic Advances in Urology* [Internet] 2021;13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117729833&doi=10.1177%2f17562872211054302&partnerID=40&md5=085741f1093e2c72643bf9a6b4a4d7f8>
43. Santini D, Cinieri S, Gasparro D, et al. Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. *Journal of Bone Oncology* [Internet] 2021;26. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098799669&doi=10.1016%2fj.jbo.2020.100341&partnerID=40&md5=d2d93ed27c00db4b643629279387e704>
44. Bersanelli M, Mazzaschi G, Giannatempo P, et al. Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). *Immunotherapy* 2021;14(2):107–14.
45. Bersanelli M, Giannarelli D, Leonetti A, et al. The right immune-modulation at the right time: Thymosin α 1 for prevention of severe COVID-19 in cancer patients. *Future Oncology* 2021;17(9):1097–104.
46. Santini D, Stellato M, De Giorgi U, et al. Clinical Outcomes of Metastatic Renal Carcinoma following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). *American Journal of Clinical Oncology: Cancer Clinical Trials* 2021;44(3):121–5.
47. Mosca A, De Giorgi U, Procopio G, et al. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: The “Pamerit” study. *Japanese Journal of Clinical Oncology* 2021;51(3):484–91.
48. Bersanelli M, Iacovelli R, Buti S, et al. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? *European Urology Oncology* 2021;4(2):274–81.
49. Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *New England Journal of Medicine* 2021;384(14):1289–300.
50. Rinchai D, Verzoni E, Huber V, et al. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. *Clinical and Translational Medicine* [Internet] 2021;11(6). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111118545&doi=10.1002%2fctm2.434&partnerID=40&md5=80e7a6931d1c18f1826f5915baba9f6c>
51. Gargiuli C, Sepe P, Tessari A, et al. Integrative transcriptomic analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma. *Cancers* [Internet] 2021;13(12). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107477515&doi=10.3390%2fcancers13122903&partnerID=40&md5=fbf0d9477433ae0f5c12bf1be0d0964a>
52. Stellato M, Santini D, Verzoni E, et al. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). *Frontiers in Oncology* [Internet] 2021;11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108320472&doi=10.3389%2ffonc.2021.682449&partnerID=40&md5=f98d51ed7cf92b28562b40e14cacbe17>
53. Kartolo A, Procopio G, Vera-Badillo FE. Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer? *European Urology Open Science* 2021;30:44–6.

54. de Velasco G, Ruiz-Granados Á, Reig O, et al. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. *BJU International* 2021;128(2):254–61.
55. Sepe P, Ottini A, Pircher CC, et al. Characteristics and treatment challenges of non-clear cell renal cell carcinoma. *Cancers* [Internet] 2021;13(15). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111294022&doi=10.3390%2fcancers13153807&partnerID=40&md5=2da988925e7d91101207f36bf1172d98>
56. Santoni M, Massari F, Grande E, et al. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. *Targeted Oncology* 2021;16(5):625–32.
57. Caminiti C, Annunziata MA, Verusio C, et al. Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients with Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial. *JAMA Network Open* [Internet] 2021;4(10). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118207473&doi=10.1001%2fjamanetworkopen.2021.28667&partnerID=40&md5=e16a8e090fb97673f7fbc1c9a37635b3>
58. Ciccicarese C, Iacovelli R, Porta C, et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. *Cancer Treatment Reviews* [Internet] 2021;100. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115621800&doi=10.1016%2fj.ctrv.2021.102295&partnerID=40&md5=58b5c66eb484a1eb09aaf609d8cfc2bb>
59. Basso U, Procopio G, Fornarini G, et al. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). *Oncology (Switzerland)* 2021;99(12):747–55.
60. Maruzzo M, Verzoni E, Vitale MG, et al. Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). *Frontiers in Oncology* [Internet] 2021;11. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120905827&doi=10.3389%2ffonc.2021.787835&partnerID=40&md5=cc28bd98bc58e3df747bdb57484fb917>
61. Ratta R, Verzoni E, Mennitto A, et al. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. *Tumori* 2021;107(6):542–9.
62. Bongiovanni A, Foca F, Fantini M, et al. First prospective data on breast cancer patients from the multicentre italian bone metastasis database. *Scientific Reports* [Internet] 2021;11(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101249573&doi=10.1038%2fs41598-021-83749-1&partnerID=40&md5=1468a0833be8b715318cc9d2b65d5058>
63. Stellato M, Procopio G, De Giorgi U, et al. Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. *Journal of Translational Medicine* [Internet] 2021;19(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112013338&doi=10.1186%2fs12967-021-03008-9&partnerID=40&md5=d2a030922c5cddb1b0ba1a5ea229c9af>
64. Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. *Annals of Oncology* 2021;32(12):1511–9.
65. Stellato M, Santini D, Cursano MC, Foderaro S, Tonini G, Procopio G. Bone metastases from urothelial carcinoma. The dark side of the moon. *Journal of Bone Oncology* [Internet] 2021;31. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120902800&doi=10.1016%2fj.jbo.2021.100405&partnerID=40&md5=c178e817a1644a79bc148eb5b701c00a>
66. Buti S, Bersanelli M, Viansone A, et al. Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radioThERapy: The together retrospective study. *Cancer Treatment and Research Communications* [Internet] 2020;22. Available from:

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074154595&doi=10.1016%2fj.ctarc.2019.100161&partnerID=40&md5=4b32d221fe7cff43ecbb52a3833153b3>

67. Santoni M, Heng DY, Bracarda S, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors. *Cancers* [Internet] 2020;12(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077345577&doi=10.3390%2fcancers12010084&partnerID=40&md5=12ab675cdab2c4782b6b198d1786c9d9>
68. Claps M, Stellato M, Zattarin E, et al. Current Understanding of Urachal Adenocarcinoma and Management Strategy. *Current Oncology Reports* [Internet] 2020;22(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078364955&doi=10.1007%2fs11912-020-0878-z&partnerID=40&md5=8a9ddd551e87fd5e85539f85f480547f>
69. Cosmai L, Porta C, Privitera C, et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. *ESMO Open* 2020;5(2):1–8.
70. Stellato M, Guadalupi V, Sepe P, et al. The emerging role of PARP inhibitors in prostate cancer. *Expert Review of Anticancer Therapy* [Internet] 2020; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089009572&doi=10.1080%2f14737140.2020.1797497&partnerID=40&md5=a908eca30ba519bd00029b3af13bd06c>
71. Procopio G, Chiuri VE, Giordano M, et al. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABlitude study. *Therapeutic Advances in Medical Oncology* [Internet] 2020;12. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094641800&doi=10.1177%2f1758835920968725&partnerID=40&md5=d17d5b9b86e32ef02935d25e8f326ce7>
72. Banna GL, Nicolai N, Palmieri G, et al. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (*Critical Reviews in Oncology / Hematology* (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006)). *Critical Reviews in Oncology/Hematology* [Internet] 2020;146. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077512241&doi=10.1016%2fj.critrevonc.2020.102865&partnerID=40&md5=ecb83610cbab8cc42412a87a9bd71eaa>
73. Bersanelli M, Buti S, Banna GL, et al. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. *Immunotherapy* 2020;12(2):151–9.
74. Cappelletti V, Verzoni E, Ratta R, et al. Analysis of single circulating tumor cells in renal cell carcinoma reveals phenotypic heterogeneity and genomic alterations related to progression. *International Journal of Molecular Sciences* [Internet] 2020;21(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079888704&doi=10.3390%2fijms21041475&partnerID=40&md5=263eaf453340fcf5644cd6ae582f0950>
75. Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. *Journal of Clinical Oncology* 2020;38(5):395–405.
76. Santini D, Berruti A, Di Maio M, et al. Bone health management in the continuum of prostate cancer disease: A review of the evidence with an expert panel opinion. *ESMO Open* [Internet] 2020;5(2). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083274261&doi=10.1136%2fesmoopen-2019-000652&partnerID=40&md5=9f6db82cf06a06c90319001632ecce1a>

77. Mennitto A, Huber V, Ratta R, et al. Angiogenesis and immunity in renal carcinoma: Can we turn an unhappy relationship into a happy marriage? *Journal of Clinical Medicine* [Internet] 2020;9(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085590121&doi=10.3390%2fjcm9040930&partnerID=40&md5=23ebcebc8941e42602db844a215bd6aa>
78. Fratino L, Procopio G, Di Maio M, Cinieri S, Leo S, Beretta G. Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. *Frontiers in Oncology* [Internet] 2020;10. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084536567&doi=10.3389%2ffonc.2020.00648&partnerID=40&md5=39e69484c4bec3829ae63ad795468bd5>
79. Porta C, Verzoni E, Zai S, et al. Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. *Tumori* 2020;106(3):257–66.
80. Marandino L, Di Maio M, Procopio G, Cinieri S, Beretta GD, Necchi A. The Shifting Landscape of Genitourinary Oncology During the COVID-19 Pandemic and how Italian Oncologists Reacted: Results from a National Survey. *European Urology* 2020;78(1):e27–35.
81. Conteduca V, Caffo O, Scarpi E, et al. Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy. *Journal of Clinical Medicine* 2020;9(6):1.
82. Brunelli C, Borreani C, Caraceni A, et al. PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: A protocol for a mixed method feasibility study. *Health and Quality of Life Outcomes* [Internet] 2020;18(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088879611&doi=10.1186%2fs12955-020-01501-1&partnerID=40&md5=7e2b1094a4acf5d1b3dc7fd954398e26>
83. Cagnazzo C, Nanni O, Arizio F, et al. Phase I studies: a test bench for Italian clinical research. *Tumori* 2020;106(4):295–300.
84. Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. *Targeted Oncology* 2020;15(4):495–501.
85. Claps M, Mennitto A, Guadalupi V, et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. *Cancer Treatment Reviews* [Internet] 2020;88. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086649786&doi=10.1016%2fj.ctrv.2020.102057&partnerID=40&md5=4e073952552649106060ae1b666ed7be>
86. Raimondi A, Sepe P, Zattarin E, et al. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. *Frontiers in Oncology* [Internet] 2020;10. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089952419&doi=10.3389%2ffonc.2020.01644&partnerID=40&md5=c8eb1fdd41c223617bbc4af5fca3d323>
87. Sepe P, Martinetti A, Mennitto A, et al. Prospective translational study investigating molecular Predictors of resistance to first-line Pazopanib in Metastatic renal Cell Carcinoma (PIPELINE Study). *American Journal of Clinical Oncology: Cancer Clinical Trials* 2020;43(9):621–7.
88. Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. *European Journal of Cancer* 2020;136:195–203.
89. Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Annals of Oncology* 2020;31(9):1119–34.
90. Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell

carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. *Cancer* 2020;126(18):4156–67.

91. Raimondi A, Sepe P, Claps M, et al. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. *Tumori* 2020;106(5):406–12.
92. Caffo O, Zagonel V, Baldessari C, et al. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. *Annals of Oncology* 2020;31(10):1415–6.
93. Iacovelli R, Ciccarese C, Facchini G, et al. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis (Targeted Oncology, (2020), 15, 4, (495-501), 10.1007/s11523-020-00732-y). *Targeted Oncology* 2020;15(5):691.
94. Caffo O, Gasparro D, Di Lorenzo G, et al. Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. *European Journal of Cancer* 2020;140:140–6.
95. Procopio G, Nichetti F, Verzoni E. Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. *The Lancet Oncology* 2020;21(12):1538–9.
96. Prisciandaro M, Ratta R, Massari F, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program. *American Journal of Clinical Oncology: Cancer Clinical Trials* 2019;42(1):42–5.
97. De Giorgi U, Cartenì G, Giannarelli D, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. *BJU International* 2019;123(1):98–105.
98. De Giorgi U, Procopio G, Giannarelli D, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. *Clinical Cancer Research* 2019;25(13):3839–46.
99. Masini C, Vitale MG, Maruzzo M, et al. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. *Clinical Genitourinary Cancer* 2019;17(1):e150–5.
100. Verzoni E, Cartenì G, Cortesi E, et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. *Journal for ImmunoTherapy of Cancer* [Internet] 2019;7(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063937275&doi=10.1186%2fs40425-019-0579-z&partnerID=40&md5=c1bd574fcf7711334a5bc654878a9d04>
101. Schmidinger M, Bamias A, Procopio G, et al. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). *Oncologist* 2019;24(4):491–7.
102. Banna GL, Nicolai N, Palmieri G, et al. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. *Critical Reviews in Oncology/Hematology* 2019;137:154–64.
103. Procopio G, Bamias A, Schmidinger M, et al. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer* 2019;17(3):e526–33.
104. Giuseppa Vitale M, Bracarda S, Cosmai L, et al. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori* 2019;105(4_suppl):3–12.
105. Sepe P, Verzoni E, Miodini P, et al. Could circulating tumor cells and ARV7 detection improve clinical decisions in metastatic castration-resistant prostate cancer? *The istituto nazionale dei tumori (INT)*

experience. *Cancers* [Internet] 2019;11(7). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071368842&doi=10.3390%2fcancers11070980&partnerID=40&md5=afd5b1a8bbb98a13bd4cdbf7efeb7a7b>

106. Apollonio G, Raimondi A, Verzoni E, et al. The role of metastasectomy in advanced renal cell carcinoma. *Expert Review of Anticancer Therapy* 2019;19(7):603–11.
107. Peverelli G, Raimondi A, Ratta R, et al. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. *Clinical Genitourinary Cancer* 2019;17(4):291–8.
108. Procopio G, Pignata S, Altavilla A, et al. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group. *Future Oncology* 2019;15(22):2657–66.
109. Pagani F, Colecchia M, Sepe P, et al. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. *Cancer Treatment Reviews* [Internet] 2019;79. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071578717&doi=10.1016%2fj.ctrv.2019.101891&partnerID=40&md5=89156d8f7c2665690dd0d576e97ce0c7>
110. Capasso A, Benigni A, Capitanio U, et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. *Kidney International* 2019;96(3):555–67.
111. Raimondi A, Randon G, Sepe P, et al. The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice. *International Journal of Molecular Sciences* [Internet] 2019;20(17). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071742571&doi=10.3390%2fijms20174263&partnerID=40&md5=3f7683175a1b9f26e1286e5f5f25f6de>
112. Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. *Prostate* 2019;79(14):1683–91.
113. Procopio G, Sepe P, Claps M, de Braud F, Verzoni E. Should we use combination therapy for all advanced renal cell carcinoma? *The Lancet Oncology* 2019;20(10):1331–2.
114. Procopio G, Apollonio G, Cognetti F, et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. *European urology oncology* 2019;2(6):699–707.
115. Raimondi A, Sepe P, Claps M, Verzoni E, Procopio G. Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma? *Expert Opinion on Biological Therapy* 2019;19(11):1107–10.
116. De Gobbi A, Biasoni D, Catanzaro M, et al. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: Single institute experience. *Tumori* 2018;104(5):388–93.
117. Verzoni E, Ratta R, Grassi P, et al. TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: Liquid biopsy for biomarkers discovery. *Tumori* 2018;104(5):401–5.
118. Procopio G, Ratta R, de Braud F, Verzoni E. Combination therapies for patients with metastatic renal cell carcinoma. *The Lancet Oncology* 2018;19(3):281–3.
119. Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: Treatment patterns from the PROxima prospective registry. *Journal of Global Oncology* 2018;2018(4):1–12.
120. Escudier B, Sharma P, McDermott DF, et al. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [*Eur Urol* 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010)).

121. Mennitto A, Verzoni E, Peverelli G, Alessi A, Procopio G. Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. *Clinical Genitourinary Cancer* 2018;16(3):e521–3.
122. Bracarda S, Galli L, Maruzzo M, et al. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. *Future Oncology* 2018;14(14):1347–54.
123. Vitale MG, Scagliarini S, Galli L, et al. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab expanded access program (EAP) in Italy. *PLoS ONE* [Internet] 2018;13(7). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049581579&doi=10.1371%2fjournal.pone.0199642&partnerID=40&md5=4cfb441e2836a39dee53283017015bdb>
124. Ratta R, Verzoni E, Di Maio M, et al. Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. *Clinical Genitourinary Cancer* 2018;16(4):e735–42.
125. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clinical Genitourinary Cancer* 2018;16(4):e945–51.
126. Bersanelli M, Giannarelli D, Castrignanò P, et al. INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDia study. *Immunotherapy* 2018;10(14):1229–39.
127. Procopio G, Sepe P, Verzoni E, Pignata S, Bamias A. Adjuvant treatment of high-risk renal cell carcinoma: The jury is still out. *Annals of Oncology* 2018;29(10):2030–2.
128. Maines F, De Giorgi U, Procopio G, et al. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program. *Future Oncology* 2018;14(26):2691–9.
129. Santini D, Ratta R, Pantano F, et al. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis. *Oncotarget* 2017;8(59):100708–16.
130. Mennitto A, Verzoni E, Calareso G, Spreafico C, Procopio G. Treatment of advanced renal cell carcinoma: Recent advances and current role of immunotherapy, surgery, and cryotherapy. *Tumori* 2017;103(1):15–21.
131. Ratta R, Prisciandaro M, Procopio G. Personalized therapy in renal cell carcinoma: Are the different tyrosine kinase inhibitors the same for any patient? *Expert Review of Precision Medicine and Drug Development* 2017;2(1):5–7.
132. Elgendy M, Abdel-Aziz AK, Renne SL, et al. Dual modulation of MCL-1 and mTOR determines the response to sunitinib. *Journal of Clinical Investigation* 2017;127(1):153–68.
133. Pusceddu S, Verzoni E, Prinzi N, et al. Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential. *Therapeutic Advances in Medical Oncology* 2017;9(3):183–8.
134. Mennitto A, Grassi P, Verzoni E, Ratta R, Procopio G. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma? *Journal of Medical Imaging and Radiation Oncology* 2017;61(2):250–1.
135. Grassi P, Doucet L, Giglione P, et al. Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. *Oncology (Switzerland)* 2017;92(5):269–75.
136. Baldari S, Boni G, Bortolus R, et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. *Critical Reviews in Oncology/Hematology* 2017;113:43–51.

137. Grassi P, Verzoni E, Ratta R, et al. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? *Drugs in R and D* 2017;17(3):461–7.
138. Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: First experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. *Annals of Oncology* 2017;28(10):2464–71.
139. Ratta R, Grassi P, Fucà G, Verzoni E, Procopio G. Castration-naïve metastatic prostate cancer: reshaping old paradigms. *Expert Review of Anticancer Therapy* 2017;17(10):879–81.
140. Mennitto A, Verzoni E, Grassi P, Ratta R, Fucà G, Procopio G. Multimodal treatment of advanced renal cancer in 2017. *Expert Review of Clinical Pharmacology* 2017;10(12):1395–402.
141. Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]. *European Urology* 2017;72(6):962–71.
142. Verzoni E, de Giorgi U, Derosa L, et al. Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: A retrospective cohort study. *Oncotarget* 2016;7(26):40085–94.
143. Magnani T, Bellardita L, Caraceni A, et al. Multidisciplinary approach of prostate cancer patients [Internet]. In: *Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management*. 2016. p. 281–93. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009684571&doi=10.1007%2f978-3-319-42327-2_21&partnerID=40&md5=580b86c2ca7943e30cad6cc91a5b8d77
144. Grassi P, Verzoni E, Mennitto A, Procopio G. Cabozantinib in advanced renal cell carcinoma: A METEOR impact on clinical practice. *Translational Andrology and Urology* 2016;5(6):974–6.
145. Mennitto A, Vernieri C, Procopio G. Urachal carcinoma: Towards a precision medicine. *Translational Cancer Research* 2016;5:S1307–10.
146. Procopio G, Ratta R, Grassi P. Evolving treatment landscape in metastatic renal cell carcinoma: Where are we now? *Expert Review of Anticancer Therapy* 2016;16(2):133–5.
147. Maines F, Caffo O, De Giorgi U, et al. Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. *Clinical Genitourinary Cancer* 2016;14(1):48–55.
148. Veccia A, Caffo O, De Giorgi U, et al. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. *Future Oncology* 2016;12(4):493–502.
149. Bracarda S, Iacovelli R, Boni L, et al. Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107–2113] (doi: 10.1093/annonc/mdv315)]. *Annals of Oncology* 2016;27(2):366.
150. Zanardi E, Grassi P, Cavo A, et al. Treatment of elderly patients with metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy* 2016;16(3):323–34.
151. Necchi A, Lo Vullo S, Mariani L, et al. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. *Investigational New Drugs* 2016;34(2):236–42.
152. Grassi P, Doucet L, Giglione P, et al. Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis. *PLoS ONE [Internet]* 2016;11(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963784539&doi=10.1371%2fjournal.pone.0151662&partnerID=40&md5=f0b7cc99798fe882bcb6d2f04cdd8d09>

153. Santini D, Santoni M, Conti A, et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. *Oncotarget* 2016;7(22):33381–90.
154. Procopio G, Ratta R, de Braud F. Improved quality of life is the way to longer life. *The Lancet Oncology* 2016;17(7):862–3.
155. Grassi P, Verzoni E, Ratta R, Mennitto A, de Braud F, Procopio G. Cabozantinib in the treatment of advanced renal cell carcinoma: Design, development, and potential place in the therapy. *Drug Design, Development and Therapy* 2016;10:2167–72.
156. Grassi P, Verzoni E, Procopio G. Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers? *Expert Review of Anticancer Therapy* 2016;16(8):803–4.
157. Ratta R, Zappasodi R, Raggi D, et al. Immunotherapy advances in uro-genital malignancies. *Critical Reviews in Oncology/Hematology* 2016;105:52–64.
158. Verzoni E, Grassi P, Ratta R, et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. *Therapeutic Advances in Medical Oncology* 2016;8(5):323–30.
159. Mennitto A, Grassi P, Ratta R, Verzoni E, Prisciandaro M, Procopio G. Nivolumab in the treatment of advanced renal cell carcinoma: Clinical trial evidence and experience. *Therapeutic Advances in Urology* 2016;8(5):319–26.
160. Fiorentini C, Fragni M, Perego P, et al. Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: A preclinical study. *Journal of Clinical Endocrinology and Metabolism* 2016;101(12):4594–602.
161. Santoni M, Conti A, Procopio G, et al. Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? *Journal of Experimental and Clinical Cancer Research* [Internet] 2015;34(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924098220&doi=10.1186%2fs13046-015-0122-0&partnerID=40&md5=6f08cce01ec32a0ef3718e1eb207f27f>
162. Santoni M, Conti A, Massari F, et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. *International Journal of Cancer* 2015;136(1):1–10.
163. Zanardi E, Verzoni E, Grassi P, et al. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. *Therapeutic Advances in Urology* 2015;7(3):152–61.
164. Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F, Procopio G. Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. *Therapeutic Advances in Urology* 2015;7(2):59–68.
165. Caffo O, De Giorgi U, Fratino L, et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study. *European Urology* 2015;68(1):147–53.
166. Iacovelli R, Sternberg CN, Porta C, et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis. *Current Drug Targets* 2015;16(2):164–70.
167. Santoni M, Conti A, Porta C, et al. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. *Journal of Urology* 2015;193(1):41–7.
168. Procopio G, Testa I, Verzoni E, et al. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: Overall results from a large cohort of patients. *Oncology (Switzerland)* 2015;88(3):133–8.

169. Pantano F, Santoni M, Procopio G, et al. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? PLoS ONE [Internet] 2015;10(4). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929493881&doi=10.1371%2fjournal.pone.0120427&partnerID=40&md5=7753e8499dfc44394499340c30198fa5>
170. Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clinical Genitourinary Cancer 2015;13(2):137–41.
171. Caffo O, De Giorgi U, Fratino L, et al. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme. BJU International 2015;115(5):764–71.
172. Iacovelli R, Farcomeni A, Sternberg CN, et al. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. Journal of Urology 2015;193(6):1905–10.
173. Santoni M, Conti A, Partelli S, et al. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology 2015;22(6):2094–100.
174. Caffo O, Ortega C, Di Lorenzo G, et al. Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger. Urologic oncology 2015;33(6):265.e15-21.
175. Raggi D, Mariani L, Giannatempo P, et al. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. Urologic Oncology: Seminars and Original Investigations 2015;33(7):332.e19-332.e24.
176. Necchi A, Farè E, Vullo SL, et al. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective from a Referral Center. Clinical Genitourinary Cancer 2015;13(4):385-391.e1.
177. Iacovelli R, Santini D, Rizzo M, et al. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association 2015;9(7-8 August):263–7.
178. Procopio G, Grassi P, Testa I, et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. American Journal of Clinical Oncology: Cancer Clinical Trials 2015;38(5):479–82.
179. Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis. Annals of Oncology 2015;26(10):2107–13.
180. Conteduca V, Caffo O, Fratino L, et al. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncology 2015;11(21):2881–91.
181. Verzoni E, Grassi P, Montone R, Galli G, Necchi A, Procopio G. TOKIO rationale and protocol: A phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Tumori 2015;101(6):701–3.
182. Ratta R, Verzoni E, Grassi P, Niger M, Procopio G. Predicting Molecular Models: Where Are We Going? EBioMedicine 2015;2(11):1594–5.
183. Pusceddu S, Indini A, Procopio G. Everolimus treatment in advanced solid tumors: A personal view. Future Science OA [Internet] 2015;1(3). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069007874&doi=10.4155%2ffso.14.1&partnerID=40&md5=a3553f19a1ee949238ef3bd36629e4bc>
184. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine 2015;373(19):1803–13.

185. Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. *Targeted Oncology* 2015;10(4):517–22.
186. Procopio G, Verzoni E, Biondani P, et al. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. *Tumori* 2014;100(1):e28–30.
187. Iacovelli R, Verzoni E, De Braud F, Procopio G. First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile. *Cancer Biology and Therapy* 2014;15(1):19–21.
188. Pusceddu S, Tessari A, Testa I, Procopio G. Everolimus in advanced solid tumors: When to start, early or late. *Tumori* 2014;100(1):e2–3.
189. Cremona M, Espina V, Caccia D, et al. Stratification of clear cell renal cell carcinoma by signaling pathway analysis. *Expert Review of Proteomics* 2014;11(2):237–49.
190. Bracarda S, Castellano D, Procopio G, et al. Axitinib safety in metastatic renal cell carcinoma: Suggestions for daily clinical practice based on case studies. *Expert Opinion on Drug Safety* 2014;13(4):497–510.
191. Iacovelli R, Verzoni E, De Braud FM, Procopio G. Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy? *Cancer Biology and Therapy* 2014;15(5):486–8.
192. Iacovelli R, Palazzo A, Procopio G, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. *British Journal of Clinical Pharmacology* 2014;77(6):929–38.
193. Bracarda S, Gernone A, Gasparro D, et al. Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer. *Future Oncology* 2014;10(6):975–83.
194. Verzoni E, Pusceddu S, Buzzoni R, et al. Safety profile and treatment response of everolimus in different solid tumors: An observational study. *Future Oncology* 2014;10(9):1611–7.
195. Grassi P, Verzoni E, Porcu L, et al. Targeted therapies in advanced renal cell carcinoma: The role of metastatic sites as a prognostic factor. *Future Oncology* 2014;10(8):1361–72.
196. Procopio G, Testa I, Iacovelli R, et al. Treatment of collecting duct carcinoma: Current status and future perspectives. *Anticancer Research* 2014;34(2):1027–30.
197. Iacovelli R, Carteni G, Milella M, et al. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. *Canadian Urological Association Journal* 2014;8(3–4):e121–5.
198. Verzoni E, Grassi P, Testa I, et al. Targeted treatments in advanced renal cell carcinoma: Focus on Axitinib. *Pharmacogenomics and Personalized Medicine* 2014;7(1):107–16.
199. Verzoni E, Pusceddu S, Buzzoni R, et al. Erratum: Safety profile and treatment response of everolimus in different solid tumors: An observational study (*Future Oncology* (2014) 10:9 (1611–1617)). *Future Oncology* 2014;10(10):1810.
200. Biondani P, Verzoni E, Torri V, et al. Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients. *Anticancer Research* 2014;34(5):2395–8.
201. Procopio G, Derosa L, Gernone A, et al. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. *Future Oncology* 2014;10(10):1741–50.
202. Testa I, Verzoni E, Grassi P, Colecchia M, Panzone F, Procopio G. Response to targeted therapy in urachal adenocarcinoma. *Rare Tumors* 2014;6(4):124–7.
203. Procopio G, Verzoni E, De Braud F. Butterfly and renal cell cancer: Out of chaos comes order. *Journal of Clinical Oncology* 2014;32(27):3083.

204. Iacovelli R, Verzoni E, Grassi P, Farcomeni A, De Braud F, Procopio G. Rationale and protocol of SOAP: A phase II study to evaluate the efficacy of Sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. *Tumori* 2014;100(6):e282–5.
205. Iacovelli R, Santoni M, De Braud F, Cascinu S, Procopio G. Highlights from the ASCO Genitourinary Symposium 2014: Focus on renal and prostate cancer. *Expert Review of Anticancer Therapy* 2014;14(12):1407–9.
206. Procopio G, Verzoni E, Bracarda S, et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): Final results of the ROSORC trial. *Annals of Oncology* 2013;24(12):2967–71.
207. Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis. *British Journal of Cancer* 2013;108(2):311–8.
208. Verzoni E, Garanzini E, Procopio G. Complete responses in advanced renal cell carcinoma: Utopia or real chance? *Clinical and Experimental Nephrology* 2013;17(1):151–2.
209. Iacovelli R, Carteni G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. *European Journal of Cancer* 2013;49(9):2134–42.
210. Sabbatini R, Ortega C, Procopio G, Masini C, Galligioni E, Porta C. Metastatic renal cell carcinoma: How to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. *Future Oncology* 2013;9(6):831–43.
211. Verzoni E, De Braud F, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach in advanced/metastatic renal cell carcinoma: Focus on the elderly population and treatment-related toxicity. *Future Oncology* 2013;9(11):1599–607.
212. Ballardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *European Urology* 2013;64(1):30–6.
213. Paglino C, Procopio G, Sabbatini R, et al. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. *Anticancer Research* 2013;33(11):4999–5004.
214. Iacovelli R, Altavilla A, Procopio G, et al. Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials. *Prostate Cancer and Prostatic Diseases* 2013;16(4):323–7.
215. Grassi P, Verzoni E, Mariani L, et al. Prognostic role of pancreatic metastases from renal cell carcinoma: Results from an Italian center. *Clinical Genitourinary Cancer* 2013;11(4):484–8.
216. Santini D, Procopio G, Porta C, et al. Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey. *PLoS ONE [Internet]* 2013;8(12). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893592812&doi=10.1371%2fjournal.pone.0083026&partnerID=40&md5=3d320e16e9bf73934c05cdc84cee01af>
217. Procopio G, Verzoni E, De Braud F. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial. *Eur Urol* 2012;61:826-33. *European Urology* 2012;62(1):e5.
218. Altavilla A, Iacovelli R, Procopio G, Cortesi E. Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert. *Therapeutic Advances in Urology* 2012;4(3):107–11.
219. Pietrantonio F, Biondani P, Verzoni E, Procopio G. Management of advanced genitourinary tumors. *Tumori* 2012;98(2):264–6.

220. Altavilla A, Iacovelli R, Procopio G, et al. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. *Cancer Biology and Therapy* 2012;13(11):1001–8.
221. Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, Debraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. *Therapeutic Advances in Urology* 2012;4(6):303–13.
222. Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E. Abiraterone acetate in castration-resistant prostate cancer. *Anti-Cancer Drugs* 2012;23(3):247–54.
223. Procopio G, Pusceddu S, Buzzoni R. Sunitinib and everolimus in pancreatic neuroendocrine tumors. *Tumori* 2012;98(3):394.
224. Biondani P, Procopio G, Pietrantonio F, De Braud F, Verzoni E. New perspectives in advanced genitourinary malignancies. *Tumori* 2012;98(2):267–9.
225. Verzoni E, Lanocita R, Procopio G. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: A case report. *Clinical Genitourinary Cancer* 2012;10(2):130–3.
226. Procopio G, Verzoni E, Iacovelli R, Colecchia M, Torelli T, Mariani L. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. *Clinical and Experimental Nephrology* 2012;16(3):464–7.
227. Procopio G, Sabbatini R, Porta C, Verzoni E, Galligioni E, Ortega C. Optimizing further treatment choices in short-and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. *Expert Review of Anticancer Therapy* 2012;12(8):1089–96.
228. Masini C, Sabbatini R, Porta C, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: A retrospective Italian survey. *BJU International* 2012;110(5):692–8.
229. Procopio G, Verzoni E, Iacovelli R, et al. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. *British Journal of Cancer* 2012;107(8):1227–32.
230. Magnani T, Valdagni R, Salvioni R, et al. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: Incidence of management changes. *BJU International* 2012;110(7):998–1003.
231. Procopio G, Verzoni E, De Braud F. Targeted therapies and survival: What we can learn from studies in advanced renal cell carcinoma. *Oncology (Switzerland)* 2012;84(1):39–42.
232. Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science. *Expert Review of Anticancer Therapy* 2012;12(12):1571–7.
233. Testa I, Verzoni E, Catanzaro M, Biasoni D, Procopio G. Castration resistant prostate cancer: The activity of non chemotherapeutic agents [Internet]. In: *Adenocarcinoma: Pathogenesis, Treatment And Prognosis*. 2012. p. 157–74. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892042257&partnerID=40&md5=76d653f15b30df4c5395a633c3725b88>
234. Pusceddu S, Milione M, Procopio G. Compassionate use of everolimus in a patient with a neuroendocrine tumor: A case report and discussion of the literature. *Oncology Research* 2011;19(8–9):403–6.
235. Mazzola R, Alù M, Leonardi V, Procopio G, Agostara B. Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: A case report. *Tumori* 2011;97(1):115–8.
236. Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: Overall results from a large experience. *Expert Review of Anticancer Therapy* 2011;11(11):1631–40.
237. Procopio G. Role of sorafenib in renal cell carcinoma: Focus on elderly patients. *Expert Review of Anticancer Therapy* 2011;11(11):1689–92.

238. Procopio G, Niger M, Testa I. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 2011;32 Suppl 2:S217-219.
239. Procopio G, Giganti MO, Guadalupi V, Testa I, Verzoni E. REPLY. *BJU International* 2011;107(8):1327.
240. Procopio G, Verzoni E, Bracarda S, et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial. *British Journal of Cancer* 2011;104(8):1256–61.
241. Procopio G, Guadalupi V, Giganti MO, et al. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. *BJU International* 2011;108(2):223–7.
242. Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: A large open-label study in diverse community settings. *Annals of Oncology* 2011;22(8):1812–23.
243. Porta C, Procopio G, Cartenì G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): An Italian multicentre retrospective analysis of 189 patient cases. *BJU International* 2011;108(8 B):E250–7.
244. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon- α 2a compared with sunitinib. *British Journal of Cancer* 2010;102(1):80–6.
245. Procopio G, Verzoni E, Guadalupi V, Iacovelli R, Bajetta E. Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? *Tumori* 2010;96(5):794–5.
246. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon- α 2a compared with sunitinib. *Journal of Urology* 2010;184(4):1303–4.
247. Procopio G, Guadalupi V, Giganti MO, et al. Prostate cancer in the elderly: Which therapy? *Geriatric and Medical Intelligence* 2010;19(1):52–7.
248. Iacovelli R, Raimondi C, Palazzo A, Cortesi E, Procopio G. Neoadjuvant targeted therapy in renal cell carcinoma. *Nature Reviews Urology* [Internet] 2010;7(7). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954490301&doi=10.1038%2fnrurol.2010.2-c1&partnerID=40&md5=c4e7fb9f01d6b9cf730aa98985b831d4>
249. Procopio G, Verzoni E, Bajetta E. Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. *Medical Oncology* 2010;27(4):1267–8.
250. Bajetta E, Catena L, Ducceschi M, et al. Pitfalls in the diagnosis of neuroendocrine tumors: Atypical clinical and radiological findings as cause of medical mistakes. *Tumori* 2009;95(4):501–7.
251. Bajetta E, Procopio G, Pusceddu S, et al. From biology to clinical experience: Evolution in the knowledge of neuroendocrine tumours. *Oncology Reviews* 2009;3(2):79–87.
252. Bajetta E, Guadalupi V, Procopio G. Activity of sunitinib in patients with advanced neuroendocrine tumors. *Journal of Clinical Oncology* 2009;27(2):319–20.
253. Procopio G, Verzoni E, Guadalupi V, Bajetta E. Sorafenib in the treatment of elderly patients affected by advanced Renal Cell Cancer (RCC). *Geriatric and Medical Intelligence* 2009;18(2):125–30.
254. Bajetta E, Procopio G, Guadalupi V, Del Vecchio M. Letter to the editor. *Clinical Therapeutics* 2009;31(9):2060–1.
255. Procopio G, Verzoni E, Gevorgyan A, et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. *Oncology* 2008;73(3–4):204–9.

256. De Dosso S, Bajetta E, Procopio G, et al. Pulmonary carcinoid tumours: Indolent but not benign. *Oncology* 2008;73(3-4):162-8.
257. Bajetta E, Procopio G, Verzoni E, et al. Renal cell cancer and sorafenib: Skin toxicity and treatment outcome. *Tumori* 2007;93(2):201-3.
258. Bajetta E, Platania M, Catena L, et al. Merkel cell carcinoma after liver transplantation: A case report. *Tumori* 2007;93(3):323-6.
259. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? *Cancer Chemotherapy and Pharmacology* 2007;59(5):637-42.
260. Procopio G, Ricotta R, Fusi A, et al. Neuroendocrine tumors of the larynx: A clinical report and literature review. *Tumori* 2006;92(1):72-5.
261. Ferrari L, Della Torre S, Collini P, et al. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. *Tumori* 2006;92(6):531-5.
262. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study. *Cancer* 2006;107(10):2474-81.
263. Valdagni R, Salvioni R, Nicolai N, et al. In regard to Kagan: "The multidisciplinary clinic" (*Int J Radiat Oncol Biol Phys* 2005;61:967-968) [3]. *International Journal of Radiation Oncology Biology Physics* 2005;63(1):309-10.
264. Bajetta E, Catena L, Procopio G, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? *Annals of Oncology* 2005;16(8):1374-80.
265. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. *Journal of Clinical Oncology* 2005;23(10):2155-61.
266. Fusi A, Procopio G, Della Torre S, et al. Treatment options in hormone-refractory metastatic prostate carcinoma. *Tumori* 2004;90(6):535-46.
267. Ferrari L, Seregni E, Lucignani G, et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. *International Journal of Biological Markers* 2004;19(4):295-304.
268. Della Torre S, Procopio G, Fusi A, et al. Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy. *Tumori* 2003;89(2):111-6.
269. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E. Update on the treatment of neuroendocrine tumors. *Expert Review of Anticancer Therapy* 2003;3(5):631-42.
270. Gattinoni L, Alù M, Ferrari L, et al. Renal cancer treatment: A review of the literature. *Tumori* 2003;89(5):476-84.
271. Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. *Annals of Oncology* 2002;13(4):614-21.
272. Bajetta E, Procopio G, Ferrari L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. *Cancer* 2002;94(2):299-304.
273. Bajetta E, Procopio G, Buzzoni R, Catena L, Ferrari L, Del Vecchio M. Advances in diagnosis and therapy of neuroendocrine tumors. *Expert Review of Anticancer Therapy* 2001;1(3):371-81.
274. Cassata A, Procopio G, Alù M, et al. Capecitabine: Indications and future perspectives in the treatment of

metastatic colorectal and breast cancer. *Tumori* 2001;87(6):364–71.

275. Bombardieri E, Maccauro M, Castellani MR, et al. Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure? *Minerva endocrinologica* 2001;26(4):197–213.
276. Bajetta E, Stani SC, De Candis D, et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma A phase II trial. *Cancer* 2000;89(4):763–8.
277. Del Vecchio M, Procopio G, Cassata A, et al. Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT. *Tumori* 1999;85(1):6–11.
278. Celio L, Martinetti A, Ferrari L, et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. *Anticancer Research* 1999;19(3 B):2261–8.
279. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. *Cancer* 1999;86(5):858–65.
280. Bajetta E, Rimassa L, Carnaghi C, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. *Cancer* 1998;83(2):372–8.
281. Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, et al. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). *Tumori* [Internet]. 2023;109:129–37. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143614330&doi=10.1177%2f03008916221138881&partnerID=40&md5=12f64c5782cb6533d5f40050d3683b67>
282. Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, et al. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. *European Urology* [Internet]. 2023;83:82–9. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139599100&doi=10.1016%2fj.eururo.2022.09.025&partnerID=40&md5=a0dbc51a3bb77ed50b74fcaedad34550>
283. Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. *Journal of Translational Medicine* [Internet]. 2023;21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147458375&doi=10.1186%2fs12967-022-03861-2&partnerID=40&md5=18d6b9965fc671c81c13061ea7598451>
284. Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. *Therapeutic Advances in Medical Oncology* [Internet]. 2023;15. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150518608&doi=10.1177%2f17588359231156147&partnerID=40&md5=fd3f8d46f94525bc41891a6d4444c5ce>
285. Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, et al. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). *Clinical Genitourinary Cancer* [Internet]. 2023; Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152672586&doi=10.1016%2fj.clgc.2023.03.006&partnerID=40&md5=6e4022886aa73bdaf626be99f7a6f691>
286. Buti S, Basso U, Giannarelli D, De Giorgi U, Maruzzo M, Iacovelli R, et al. Concomitant Drugs Prognostic

Score in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. *Journal of Immunotherapy* [Internet]. 2023;46:22–6. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143644394&doi=10.1097%2fCJI.0000000000000446&partnerID=40&md5=8150b74b4e232714b96a2b7deac8c8c1>

287. Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, et al. Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma. *Current Oncology Reports* [Internet]. 2023;25:671–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151444264&doi=10.1007%2fs11912-023-01395-4&partnerID=40&md5=4a033b82205bda29b15d1f0278d8ca53>
288. Berruti A, Bracarda S, Caffo O, Cortesi E, D'Angelillo R, Del Re M, et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. *Cancer Treatment Reviews* [Internet]. 2023;115. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149971025&doi=10.1016%2fj.ctrv.2023.102525&partnerID=40&md5=b63dc23980d497a3fa824c82527f6473>
289. Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, et al. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. *Clinical cancer research : an official journal of the American Association for Cancer Research* [Internet]. 2023;29:92–9. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145492553&doi=10.1158%2f1078-0432.CCR-21-3577&partnerID=40&md5=7e4558d91d74f6b29851ed515e88eb08>
290. Stellato M, Buti S, Maruzzo M, Bersanelli M, Pierantoni F, De Giorgi U, et al. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). *International Journal of Molecular Sciences* [Internet]. 2023;24. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85146648874&doi=10.3390%2fijms24021096&partnerID=40&md5=18f31a17367d2f5169b5912ddf996982>
291. Bazzocchi MV, Zilioli C, Gallone VI, Commisso C, Bertolotti L, Pagnini F, et al. The Role of CT Imaging in Characterization of Small Renal Masses. *Diagnostics* [Internet]. 2023;13. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147809358&doi=10.3390%2fdiagnostics13030334&partnerID=40&md5=b11f543ca30d0b2b040203490fb74bcd>

Last update: 15/06/2023,
Scopus data, more than 10.000, H/INDEX 40

Milano, 15/6/2023